在心血管健康领域，降低低密度脂蛋白胆固醇（LDL-C）和载脂蛋白 B（Apo B）水平是预防心血管疾病的关键策略。长期以来，他汀类药物作为标准治疗手段，已在临床上显著降低了心血管疾病的风险，但其疗效仍存在一定的局限性。 针对这一现状，美国克利夫兰诊所的心脏病专家 Leslie Cho 医学博士，在第 74 届美国心脏病学会科学年会（ACC.25）上，将重点介绍超越他汀类药物的新治疗方案。这些方案旨 ...

JE: We are excited to rapidly progress towards initial results from our ongoing phase 3 program (ODYSSEY) with our investigational PCSK9-inihibitor alirocumab. "PCSK9 inhibition represents an ...

Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

Statins are often prescribed to lower cholesterol levels, but not everyone responds to statin treatment. Other medications, such as sequestrants, PCSK9 inhibitors, cholesterol absorption ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

再生元制药公司现在的股价报632.03 再生元制药公司的股票在哪间交易所挂牌交易？ 再生元制药公司的股票在纳斯达克挂牌交易。 再生元制药公司的股票代码是什么？ 再生元制药公司的股票代码是“REGN。” 再生元制药公司有分红吗？当前的股息收益率是多少 ...

Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the american heart association ...

Background The link between low-density lipoprotein cholesterol (LDL-C) levels and dementia risk is poorly understood, with conflicting evidence on the role of LDL-C and the impact of statin therapy ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Numerous studies have shown that dyslipidemia increases the risk of atherosclerotic cardiovascular disease (ASCVD) and significantly impacts the occurrence and progression of diabetic kidney disease ...